stockrow
Friday 6 November 2026
Export SEPN’s income statement to Excel — free account
Septerna, Inc.
SEPN Healthcare Biotechnology
Septerna, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $46.0 million, up 4,174.5% from fiscal 2024.
- Revenue
- +22,375.6%
- EPS
- +48.2%
- Free cash flow
- −9.01%
Quarter to June 2026, against a year earlier
49.54
2.19
+4.63%
Follow SEPN
Alert me
Septerna, Inc. (SEPN) Free cash flow margin
Septerna, Inc.'s free cash flow margin over the twelve months to 30 June 2026 was 118.9%, down 146.9 percentage points from fiscal 2025 (265.9%). That is above the Biotechnology industry median of 0.00% and above the Healthcare sector median of 0.00%.
Free cash flow margin, annual
Embed this chart
Annual newest first
| Period | Free cash flow margin | Change (points) |
|---|---|---|
| FY2025 | 265.9% | 4,633.13 |
| FY2024 | −4,367.3% | 6,626.78 |
| FY2023 | −10,994.0% | — |
Free cash flow margin against peers
| Company | Free cash flow margin |
|---|---|
| SEPN Septerna, Inc. | 118.9% |
| AUPH Aurinia Pharmaceuticals Inc compare | 55.0% |
| VCEL Vericel Corporation compare | 17.9% |
| IMNM Immunome, Inc. compare | 0.00% |
| VERA Vera Therapeutics, Inc. compare | 0.00% |
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | 0.00% |
| BHVN Biohaven Ltd. compare | 0.00% |
| PVLA Palvella Therapeutics, Inc. compare | 0.00% |
| ZYME Zymeworks Inc. compare | −324.7% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Free cash flow margin is
Free Cash Flow Margin tells an investor how much of each sale turns into cash the company keeps after paying for investment in its assets.
(Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)) ÷ Revenue
More on SEPN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- The full statement